Sofosbuvir is a viral polymerase nucleotide inhibitor that was approved in December2013 by the United States Food and Drug Administration (FDA), and in January 2014by the European Medicines Agency for the treatment of HCV infection [1]. The WHOGuidelines for the screening, care and treatment of persons with hepatitis C infectionrecommend sofosbuvir in combination with ribavirin in genotypes 1, 2, 3 and 4 HCVinfection, either with or without pegylated interferon (depending on the HCV genotype)...